Drug Profile
Talabostat - BioXcel Therapeutics
Alternative Names: BXCL 701; PT-100; Talabostat mesilate; Talabostat mesylate; Val-boro-ProLatest Information Update: 15 Feb 2024
Price :
$50
*
At a glance
- Originator Tufts University School of Medicine
- Developer BioXcel Therapeutics; Georgetown University; M. D. Anderson Cancer Center; Midatech Pharma US; National Cancer Institute (USA); OnkosXcel Therapeutics
- Class Antineoplastics; Boronic acids; Dipeptides; Pyrrolidines; Small molecules
- Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Dipeptidyl peptidase 8 inhibitors; Dipeptidyl peptidase 9 inhibitors; Fibroblast activation protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Adenocarcinoma; Prostate cancer; Solid tumours
- Phase I/II Pancreatic cancer
- Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
- Preclinical Small cell lung cancer; Soft tissue sarcoma
- Discontinued Chronic lymphocytic leukaemia; Malignant melanoma; Neutropenia; Non-small cell lung cancer
Most Recent Events
- 12 Feb 2024 Talabostat - BioXcel Therapeutics receives Fast Track designation for Prostate cancer [PO,Tablet] (Hormone refractory, Combination therapy, Second-line therapy or greater, Treatment-naive) in USA
- 10 Oct 2023 Efficacy data from a phase IIb trial in Prostate cancer released by BioXcel Therapeutics
- 01 Jul 2023 Phase-II clinical trials in Adenocarcinoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT05558982)